B+
Bull case
20%
Probability
Target price
$8.20
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
HBIO
Harvard BioscienceDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 print provides real operating support for a cautious constructive view: revenue growth accelerated, adjusted EBITDA improved, and management raised full-year revenue guidance while maintaining its EBITDA-growth target. Continued CMT and NPI momentum, Project Viking savings, and balance-sheet stabilization could support a modest re-rating.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Financing, covenant, warrant-overhang, and liquidity risks remain important for a micro-cap issuer; sustained compliance and cash conversion are not yet established. [#10-Q-2026-05-12][#10-K-2026-03-13]
Momentum
94
Value
54
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.20 · Bull $8.20 · Bear $4.80Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum94 · Δ7d -
Value54 · Δ7d -0.0
Sentiment45 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Financing, covenant, warrant-overhang, and liquidity risks remain important for a micro-cap issuer; sustained compliance and cash conversion are not yet established. [#10-Q-2026-05-12][#10-K-2026-03-13]
- • Lower-margin CMT and geographic mix can pressure adjusted gross margin despite revenue growth. [#SEC-8K-2026-08-11]
- • The company remains loss-making, six-month operating cash flow was negative, adjusted gross margin faced mix pressure, and the balance-sheet/self-help thesis still requires execution.
Catalyst clock
2026-08-11
Q2 growth and raised full-year revenue outlook
Lead driver: Sentiment · See AI snapshot
Momentum
94
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
54
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-9.6
Sentiment
45
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 93.7 / Value 53.8 / Sentiment 44.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$7.20
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$29.59M
Beta
1.55
Shares Out
4.55M
P/E (TTM) · Derived
-0.5
P/S (TTM)
0.35
P/FCF (TTM)
4.47
Rev YoY
+11.1%
EPS YoY
+24.8%
Gross Margin
+54.3%
Op Margin
+0.7%
Net Debt
$35.66M
Current Ratio
1.87
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data